What are the long-term side effects of Gazyva?
Long-term side effects associated with Gazyva (obinutuzumab) use can include prolonged low blood counts, infusion-related reactions, and potential reactivation of hepatitis B infections [1][2]. Patients may also experience an increased risk of infections due to the drug's mechanism of action [2].
What is Gazyva used for?
Gazyva is a B-cell targeted therapy used in combination with chemotherapy to treat certain types of B-cell chronic lymphocytic leukemia (CLL) and for previously untreated follicular lymphoma (FL) [1]. It is also used as a single agent for certain patients with FL who have relapsed or are refractory after at least two prior systemic therapies [1].
How does Gazyva work?
Gazyva is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells. By binding to CD20, it marks these cells for destruction by the body's immune system, thereby reducing the number of cancerous B-cells [1].
What are the common side effects of Gazyva?
Common side effects reported with Gazyva treatment include infusion-related reactions, low neutrophil counts (neutropenia), low platelet counts (thrombocytopenia), and anemia [1][2]. Other frequently observed side effects are nausea, fever, cough, diarrhea, and musculoskeletal pain [2].
What are infusion reactions with Gazyva?
Infusion-related reactions are a common side effect of Gazyva and can occur during or shortly after the infusion. Symptoms may include fever, chills, rash, shortness of breath, and changes in blood pressure. These reactions are typically managed by slowing or temporarily stopping the infusion and administering supportive medications [1][2].
Can Gazyva cause infections?
Yes, Gazyva can increase the risk of infections because it depletes B-cells, which are important for the immune system's function [2]. Patients should be monitored for signs of infection, and any new or worsening infections should be reported to a healthcare provider [1].
What is the risk of hepatitis B reactivation with Gazyva?
There is a risk of hepatitis B virus (HBV) reactivation in patients treated with Gazyva. Before starting treatment, patients should be tested for current or past HBV infection. For those who are positive for HBV, preventive antiviral therapy may be recommended to reduce the risk of reactivation [1][2].
How long is Gazyva treatment?
The duration of Gazyva treatment varies depending on the specific diagnosis and treatment regimen. For CLL, it is typically administered in combination with chemotherapy for a defined period. For follicular lymphoma, treatment cycles can extend over several months [1].
What are Gazyva's drug interactions?
Information regarding specific drug interactions for Gazyva is available in its prescribing information. It is crucial for patients to inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements [1].
How is Gazyva administered?
Gazyva is administered intravenously (IV) through an infusion [1]. The infusion is typically given in a healthcare setting by a trained professional [2].
What patient concerns are associated with Gazyva?
Patient concerns often revolve around the potential for side effects, including infusion reactions and increased susceptibility to infections. The possibility of long-term effects on blood counts and the need for ongoing monitoring are also significant considerations [1][2].
---
Sources:
[1] https://www.gazyvahcp.com/
[2] https://www.gene.com/media/products/gazyva